Hydroxyzine has not been singled out in a dedicated clinical trial measuring its independent effect on dementia risk, but it belongs to a drug class, first-generation antihistamines with strong anticholinergic activity, that has been repeatedly associated with higher dementia rates in large population studies. The concern is not theoretical: research tracking thousands of older adults over years has found a dose-response pattern in which heavier cumulative use of anticholinergic medications correlates with a meaningful rise in dementia diagnoses. Whether hydroxyzine deserves unique blame or simply shares in a class-wide problem is a question the evidence hasn’t fully separated, but the pharmacology gives good reason for caution.
What Makes Hydroxyzine an Anticholinergic
Hydroxyzine is prescribed for anxiety, itching, and sometimes insomnia. It works partly by blocking histamine receptors, which is how it reduces allergic symptoms and causes drowsiness. But it also blocks acetylcholine receptors in the brain. Acetylcholine is a chemical messenger that plays a central role in memory, attention, and learning. When a drug interferes with that signaling, the short-term effects can include confusion, drowsiness, and difficulty concentrating. The worry about dementia is essentially about what happens when that interference is repeated over months or years.
Not all antihistamines carry the same anticholinergic load. Newer, second-generation antihistamines like cetirizine (which is actually a metabolite of hydroxyzine) and loratadine were designed to stay mostly outside the brain, reducing the sedation and cognitive side effects. Hydroxyzine, as a first-generation drug, crosses into the brain more readily, which is why it causes noticeable drowsiness and why clinicians have become increasingly wary of prescribing it to older adults. A clinical review on anticholinergic effects in aging found that nearly all studies showed a link between medications with anticholinergic activity and cognitive problems, ranging from delirium to frank dementia.1PubMed Central. The cognitive impact of anticholinergics: A clinical review
What Large Population Studies Have Found
The strongest evidence connecting anticholinergic drugs to dementia comes from observational studies that followed large groups of people over many years. A landmark study tracked over 3,400 older adults for an average of about seven years. Roughly 23% developed dementia during that period. The researchers measured cumulative anticholinergic exposure using a standardized daily dose metric, and the pattern was striking: people in the highest exposure group had about a 54% greater risk of developing dementia compared to those with no anticholinergic use. The relationship followed a clear dose-response curve, meaning the more total exposure someone accumulated, the higher their risk climbed.2PubMed Central. Cumulative Use of Strong Anticholinergic Medications and Incident Dementia
A separate validation study using a Korean population found a similar pattern. After adjusting for other health factors, people with the highest anticholinergic burden had roughly 70% higher odds of developing dementia compared to those with minimal exposure.3PubMed Central. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale The fact that the dose-response relationship holds across different populations and different anticholinergic scoring systems strengthens the case that this is a real biological effect rather than a statistical quirk.
An important caveat: these studies measure anticholinergic drugs as a class, lumping hydroxyzine together with drugs like oxybutynin (for overactive bladder), older antidepressants, and diphenhydramine (the active ingredient in many over-the-counter sleep aids). Hydroxyzine is rated as a strong anticholinergic on most standard scales, placing it in the same risk tier as these other medications. But no major study has isolated hydroxyzine’s contribution from the rest of the class. The evidence says that the type of brain activity hydroxyzine produces, when accumulated in sufficient quantity over time, is associated with dementia. It doesn’t say hydroxyzine is worse or better than other strong anticholinergics.
How Anticholinergics May Physically Damage the Brain
The observational data would be less convincing on its own, but animal research has uncovered plausible biological mechanisms that could explain how anticholinergic drugs contribute to neurodegeneration rather than just masking symptoms temporarily. In a mouse model of tau-related brain disease (tau is one of the key proteins that misfolds and accumulates in Alzheimer’s), administering anticholinergic drugs markedly increased tau pathology, loss of synapses, and neurodegeneration in the hippocampus, the brain region most critical for forming new memories. The anticholinergic-treated mice also showed activation of immune cells in the brain called microglia, along with increased levels of inflammatory signaling molecules.4PubMed. Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model
This points to a two-pronged problem. First, blocking acetylcholine directly impairs brain function in the short term. Second, and more worrying for long-term risk, anticholinergic activity appears to suppress the brain’s own anti-inflammatory defenses. Acetylcholine normally helps keep neuroinflammation in check; when that brake is removed by anticholinergic drugs, inflammatory processes can accelerate. A review of this research noted that the neurodegeneration seen in animal models matched the pattern of microglial activation, and that amyloid-beta, the other hallmark protein in Alzheimer’s disease, itself depletes cholinergic function in a way that resembles what anticholinergic drugs do. The implication is that anticholinergic exposure might not just worsen existing Alzheimer’s pathology but could potentially initiate or speed it up.5PubMed. Does Anticholinergic Activity Affect Neuropathology? Implication of Neuroinflammation in Alzheimer’s Disease
Animal studies don’t automatically translate to humans, of course. But the convergence of epidemiological data showing dose-dependent risk increases and bench research showing plausible biological pathways makes the overall case considerably harder to dismiss as coincidence.
Why Older Adults Face Disproportionate Risk
The concern about hydroxyzine and similar drugs becomes particularly acute in people over 65, and the reasons are layered. The aging brain naturally loses cholinergic neurons and receptors, so any drug that further suppresses acetylcholine is hitting a system that already has less room to compensate. It’s the difference between dimming lights in a well-lit room versus dimming them in a room that’s already fairly dark.1PubMed Central. The cognitive impact of anticholinergics: A clinical review
On top of that, the blood-brain barrier, which normally controls what substances get from the bloodstream into the brain, becomes leakier with age. Research on the aging blood-brain barrier has linked deficits in this barrier’s integrity to medication-related cognitive decline, among other geriatric syndromes.6PubMed Central. The blood-brain barrier: geriatric relevance of a critical brain-body interface So the same dose of hydroxyzine that might produce mild drowsiness in a 30-year-old could deliver a substantially larger anticholinergic hit to the brain of a 75-year-old. Combine that with slower liver metabolism and kidney clearance in older adults, meaning the drug stays active in the body longer, and you have a situation where a standard prescription can produce outsized effects.
A geriatric clinical review put it plainly: first-generation antihistamines like hydroxyzine, diphenhydramine, and chlorpheniramine should be avoided in older adults because of significant anticholinergic side effects including sedation, confusion, urinary retention, and constipation.7PubMed Central. Pruritus in the elderly: clinical approaches to the improvement of quality of life The American Geriatrics Society’s Beers Criteria, which is the most widely used list of medications considered potentially inappropriate for older adults, includes hydroxyzine for these reasons.
How Much Use It Takes to Matter
One of the most useful findings from the population studies is that the risk appears to depend on cumulative exposure, not just whether you’ve ever taken the drug. In the study that tracked anticholinergic use over ten years, the lowest cumulative exposure group showed no statistically meaningful increase in dementia risk. The risk started to become noticeable at moderate exposure levels and became clearly elevated in the highest exposure category, which corresponded to taking a strong anticholinergic daily for roughly three years or more.2PubMed Central. Cumulative Use of Strong Anticholinergic Medications and Incident Dementia
This has practical implications. If you’ve taken hydroxyzine occasionally for a few weeks to manage an allergic reaction or a short bout of anxiety, the evidence suggests your long-term cognitive risk is not substantially different from someone who never took it. The concern is really directed at chronic use: people who take hydroxyzine nightly for sleep for years, or who use it regularly to manage ongoing anxiety or itching alongside other anticholinergic medications they may not realize are contributing to the same cumulative load. Over-the-counter sleep aids containing diphenhydramine, certain bladder medications, and some older antidepressants all add to the total anticholinergic burden.
If you’re worried about your own exposure, it’s worth cataloging all the medications you take, including over-the-counter ones, and asking a pharmacist to check the total anticholinergic score. Many people are surprised to learn they’re accumulating anticholinergic exposure from multiple sources simultaneously.
Hydroxyzine’s Prevalence Where It Matters Most
One troubling finding is how commonly hydroxyzine appears in settings where cognitive protection should be a priority. A cross-sectional study of nursing home dementia units found that hydroxyzine, promethazine, and alimemazine together accounted for about 59% of anticholinergic drug use among residents.8PubMed Central. Medications causing potential cognitive impairment are common in nursing home dementia units – A cross-sectional study In other words, people who already have dementia are frequently being given the very class of drugs most associated with worsening cognitive function. This often reflects the practical reality that these medications are inexpensive, familiar, and effective at managing agitation or itching, which are common problems in dementia care. But it highlights a gap between what the research suggests and how medications are actually prescribed on the ground.
Genetic Factors That Affect Your Vulnerability
Not everyone metabolizes hydroxyzine at the same rate, and emerging pharmacogenetic research suggests this variation matters. Hydroxyzine is primarily broken down by liver enzymes, particularly CYP2D6. People carry different genetic variants of CYP2D6 that make the enzyme work faster, slower, or not at all. A study examining how CYP2D6 gene variants relate to anticholinergic side effects found that individuals carrying certain reduced-function variants had significantly higher anticholinergic drug burden scores and more pronounced side effects like severe dry mouth. In that study, carrying just one copy of a particular CYP2D6 risk variant was associated with substantially higher anticholinergic burden compared to people with the normal-functioning version of the gene.9PubMed Central. Pharmacogenetic associations of CYP2D6 and CYP2C19 variants with anticholinergic drug burden and hyposalivation
What this means in practical terms is that two people taking the same dose of hydroxyzine could experience very different levels of anticholinergic effect in their brains. A person who is a “poor metabolizer” due to their CYP2D6 genotype will clear the drug more slowly, resulting in higher and longer-lasting blood levels from each dose. Over months and years, that slower clearance could translate to substantially greater cumulative anticholinergic exposure than their prescription alone would suggest. Pharmacogenomic testing is becoming more accessible, and for someone considering long-term use of hydroxyzine or other anticholinergics, knowing their CYP2D6 status could help a prescriber fine-tune the dose or choose a different medication entirely.
Safer Alternatives for Common Uses
The good news is that for most of hydroxyzine’s common uses, there are alternatives that carry less anticholinergic baggage. For allergy management, second-generation antihistamines like cetirizine, loratadine, and fexofenadine provide effective symptom control with minimal brain penetration. Cetirizine is directly derived from hydroxyzine but was engineered to stay largely outside the central nervous system, which is why it causes much less sedation.
For anxiety, the picture is more complicated. Hydroxyzine is sometimes prescribed specifically because it is not a benzodiazepine and not considered addictive, making it attractive for patients with substance use histories or for those who want to avoid the dependency risks of drugs like lorazepam. SSRIs and SNRIs remain first-line treatments for generalized anxiety, and buspirone is another non-addictive option without anticholinergic effects, though it takes weeks to reach full effectiveness. Cognitive behavioral therapy also has strong evidence for anxiety and carries no pharmacological risk at all.
For sleep, hydroxyzine’s sedating effects have made it a common off-label choice, but the same anticholinergic properties that cause drowsiness are exactly what raises cognitive concerns. Melatonin, good sleep hygiene, and cognitive behavioral therapy for insomnia are generally preferred starting points, particularly in older adults. When a sedating medication is truly needed, prescribers increasingly reach for options with lower anticholinergic profiles.
For itching in older adults, topical treatments like emollients, low-dose topical corticosteroids, or newer targeted therapies can often manage symptoms without systemic anticholinergic exposure. When an oral antihistamine is necessary, second-generation options are the recommended choice for this population.7PubMed Central. Pruritus in the elderly: clinical approaches to the improvement of quality of life
Racial Disparities in Who Gets Prescribed Anticholinergics
An underappreciated aspect of this issue is that anticholinergic prescribing is not evenly distributed across populations. A study of community-dwelling older adults found that Black Americans were significantly less likely to be prescribed anticholinergic medications than white Americans, even after adjusting for age, sex, education, and overall health. At baseline, Black participants were about 33% less likely to be using anticholinergics, and that gap widened over ten years, at which point they were 45% less likely to be taking these drugs.10PubMed Central. Racial Differences in Anticholinergic Use among Community-Dwelling Elders
At first glance, lower anticholinergic use might seem protective. But this pattern appears to reflect broader healthcare access and prescribing disparities rather than targeted clinical decision-making. A separate analysis of overactive bladder prescriptions found that Black patients, especially Black women, were much more likely to be prescribed older anticholinergic bladder medications than newer alternatives with fewer cognitive side effects. Black women had 90% lower odds of receiving a newer-class bladder medication compared to white women.11JAMA Network Open. Inequities in Filled Overactive Bladder Medication Prescriptions in the US So when Black patients do receive treatment for conditions like overactive bladder, they are disproportionately channeled toward the higher-risk anticholinergic options rather than the newer drugs with better cognitive safety profiles. The pattern is complicated: less anticholinergic use overall, but worse options when anticholinergics are used. Both sides of that coin have implications for long-term cognitive health.